Pembrolizumab
Reading tools
Approved by the FDA on 4 September 2014, Keytruda is used for melanoma unresponsive to other drugs, progressing or unresectable. Melanoma is cancer of melanocytes, which give skin its color. It acts by preventing intracellular activity of PD1, a molecule involved in suppressing immunity.
Although Keytruda is the sixth drug approved for melanoma since 2011, it is the first acting on the cellular pathway. It causes the general side effects associated with most immunotherapy drugs.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.